Cooper Companies Forecasts $4.3B Fiscal 2026 Revenue in Midpoint Guidance
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
cooper-companiescoopersurgical
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Medical device firm The Cooper Companies, Inc. announced a fiscal 2026 revenue forecast on June 5, 2026. The company projects revenue will land between $4.28 billion and $4.32 billion. This announcement was made concurrent with an update on the ongoing strategic review of its CooperSurgical unit. The forecast provides a clear financial target for investors as the company evaluates a significant portfolio decision.
The medical device sector is navigating a complex environment of moderating inflation and sustained demand for elective procedures. The 10-year U.S. Treasury yield recently traded at 4.31%, providing a stable backdrop for growth equity valuations. Cooper's decision to initiate a strategic review of CooperSurgical follows a trend of healthcare conglomerates streamlining operations to sharpen focus on core, higher-margin businesses.
Similar portfolio optimizations have occurred across the industry. In late 2025, Johnson & Johnson completed the spin-off of its consumer health division, Kenvue, to concentrate on pharmaceuticals and medtech. Baxter International also divested its BioPharma Solutions unit for $4.25 billion in early 2026 to reduce debt and focus on core hospital products. Cooper's review aligns with this broader strategic shift toward operational focus.
The catalyst for Cooper's specific announcement is the approaching end of its fiscal year. Providing forward guidance allows the company to set investor expectations. It also demonstrates management's confidence in the stability of its foundational contact lens business amidst the uncertainty of the CooperSurgical outcome.
Cooper's $4.3 billion midpoint revenue forecast represents a projected year-over-year growth of approximately 6.5%. This growth rate is slightly above the broader medical devices industry's average, which analysts project at around 5.2% for 2026. The company's flagship CooperVision contact lens division reported a 7% revenue increase in its last quarterly earnings.
The CooperSurgical unit, now under review, contributed roughly $1.2 billion in revenue during fiscal 2025. This constitutes nearly 30% of the company's total annual revenue. The unit's portfolio includes fertility and women's health products, which have experienced volatile demand. For comparison, peer company Hologic, which focuses on women's health, reported a 4.8% revenue growth in its most recent quarter.
| Metric | Cooper Companies (Projected FY2026) | Industry Average (2026 Est.) |
|---|---|---|
| Revenue Growth | ~6.5% | ~5.2% |
| Operating Margin | 21.5% (est.) | 19.8% |
Cooper's current market capitalization stands at approximately $21.4 billion. The stock trades at a forward price-to-earnings ratio of 24x, a slight premium to the S&P 500 healthcare sector's average of 22x.
The reaffirmed growth guidance for the core business suggests stability even if CooperSurgical is divested. This outlook is a positive indicator for pure-play contact lens suppliers like Alcon (ALC) and Johnson & Johnson Vision (JNJ), as it reinforces sustained demand in the vision care market. A successful sale or spin-off of CooperSurgical could unlock value, potentially providing a one-time cash infusion estimated between $3 billion and $5 billion.
Potential acquirers for the CooperSurgical unit include large-cap medtech firms seeking to bolster their women's health portfolios. Companies like Danaher (DHR) or Thermo Fisher Scientific (TMO) could be logical suitors, though antitrust scrutiny would be a consideration. Fertility-focused smaller caps like Organogenesis (ORGO) could see increased investor interest as M&A activity in the niche heats up.
A primary risk to this thesis is execution. A divestiture is complex and could disrupt operations, potentially causing the company to miss its lofty revenue targets. The forecast hinges on a smooth process, which is not guaranteed. Institutional flow data indicates a neutral positioning in COO stock, with some hedge funds taking long positions in anticipation of a value-unlocking event.
The primary near-term catalyst is the conclusion of the CooperSurgical strategic review. Management indicated an update is expected before the Q4 earnings call, scheduled for late September 2026. The nature of the outcome—a full sale, a spin-off, or a retained business—will directly impact the stock's direction.
The next Federal Open Market Committee meeting on July 26, 2026, will also be critical. Interest rate decisions influence the cost of capital for potential acquirers and the valuation multiples applied to growth stocks like Cooper. A dovish hold or cut could facilitate a more favorable deal environment.
Investors should monitor the $380 share price level, which has acted as technical support. A sustained break above $420, the 52-week high, would likely require a positive resolution to the strategic review and confirmation of the full-year guidance.
Retail investors should view the $4.3 billion revenue forecast as a sign of underlying strength in the core contact lens business, regardless of the CooperSurgical outcome. It provides a baseline for valuation. The strategic review introduces event-driven volatility, making the stock more suitable for investors with a higher risk tolerance who can withstand potential price swings based on merger and acquisition news.
The projected 6.5% growth represents an acceleration from the company's 5-year compound annual growth rate of approximately 5.8%. This suggests management expects to gain market share or benefit from new product launches in its vision segment. The forecast notably excludes any potential contribution from CooperSurgical, implying even stronger growth in the remaining business.
Major medtech spin-offs have a mixed record. Baxter's spin-off of Baxalta in 2015 initially created significant shareholder value before Baxalta was acquired. Conversely, Zimmer Biomet's spin-off of dental unit ZimVie in 2022 struggled due to high debt loads and market saturation. The success often hinges on the spun-off entity's balance sheet strength and market position, which will be key details to watch in Cooper's case.
Cooper's revenue guidance demonstrates core business strength ahead of a pivotal portfolio decision.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.